Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Advantages of Sourcing Biosimilars vs. Branded Biologics in Clinical Trials | Contract Pharma

What are you searching for?

Sign in
Sponsored Content

Advantages of Sourcing Biosimilars vs. Branded Biologics in Clinical Trials

Released By Catalent

When a biologic drug is being studied in a clinical trial, the sponsor may want to compare the investigational product to a current standard of care, known as a comparator drug. In other cases, a co-medication may need to be dosed along with the study drug. Sourcing commercially available branded biologics can be challenging for a variety of reasons, such as high costs and limited or lack of availability. Biosimilars can be used in place of a branded drug (if one exists), offering the sponsor a variety of benefits. But what is a biosimilar, exactly? Can a sponsor just replace the branded drug with the biosimilar, or are there certain requirements that need to be met in order to use it in a clinical trial?

Learn more about:

  • The formulation comparison between a biosimilar and a branded biologic.
  • The cost, availability, and supply chain benefits of using a biosimilar.
  • Proactive steps to take that will allow a biosimilar to be used in a clinical trial.

Request more information from Catalent

Request more information from Catalent

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics